[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"amnestic-symptoms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:amnestic-symptoms":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,52],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":34,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100265889","molecular-and-structural-imaging-in-alzheimers-disease-a-longitudinal-study-100265889",false,"NCT02740634","Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study","Inclusion Criteria:\n\n* Over the age of 21\n* Must have an informant who will be able to provide independent evaluation of functioning\n* English is primary language\n* All subjects must have insidious onset, report progression of their symptoms, and meet current clinical diagnostic criteria for typical amnestic AD or an atypical AD syndrome such as Logopenic Aphasia (LPA) or Posterior Cortical Atrophy (PCA).\n* All subjects with Logopenic Aphasia (LPA) must present with early and dominant impairments in language\n* All subjects with typical amnestic AD must have relative preservation of episodic memory compared to impairment in the non-episodic memory domain\n\nExclusion Criteria:\n\n* If you have had a stroke or tumor that could explain your symptoms\n* Subjects that present with early episodic memory impairment or meet clinical criteria for mild cognitive impairment will not be recruited into the study\n* Subjects that meet specific criteria for another neurodegenerative disorder, including behavioral variant frontotemporal dementia, semantic dementia, primary progressive apraxia of speech, probable corticobasal syndrome, or progressive supranuclear palsy, will be excluded\n* Subjects will be excluded if they have poor vision (20\u002F400)\n* Women that are pregnant or post-partum and breast-feeding will be excluded\n* Subjects will be excluded from the study if they are unable to undergo the tau-PET scan due to a prolonged QT interval on ECG, or if they have any of the following genetic conditions which can increase the chance of cancer: Cowden disease, Lynch syndrome, hypogammaglobulinemia, Wiskott-Aldrich syndrome, and Down's syndrome\n* Subjects will also be excluded if MRI is contraindicated (metal in head, cardiac pace maker, e.t.c.), if there is severe claustrophobia, if there are conditions that may confound brain imaging studies (e.g. structural abnormalities, including subdural hematoma or intracranial neoplasm), or if they are medically unstable or are on medications that might affect brain structure or metabolism,(e.g. chemotherapy)","ALL","21 Years","80 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"NA","This is a neuroimaging study designed to learn more about amyloid and tau burden in the brain of patients with typical and atypical Alzheimer's Disease and how burden may change over a one year period.",[26,27,28,29,30,31,32,33],"Atypical Alzheimer's Disease","Logopenic Progressive Aphasia (LPA)","Posterior Cortical Atrophy (PCA)","Alzheimer Disease","Alzheimer Disease, Early Onset","Amnestic Disorder","Amnestic Symptoms","Amnestic Mild Cognitive Disorder",[35,36,37,38],"PCA","LPA","AD","Amnestic AD","RECRUITING","2026-07-16",{"date":42,"type":43},"2026-07-17","ACTUAL",{"date":45,"type":4},"2016-05",{"date":47,"type":20},"2027-03",{"name":49,"class":50},"Mayo Clinic","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":15,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":21,"phases":64,"briefSummary":66,"conditions":67,"keywords":70,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":51},"100557453","early-phase-1-transcranial-magnetic-stimulation-treatment-for-alzheimers-disease-100557453","NCT06538311","Transcranial Magnetic Stimulation Treatment for Alzheimer's Disease","Neuromodulation of Brain Function in Alzheimer's Disease and Related Dementias","Inclusion Criteria:\n\n1. Between the ages of 40-99\n2. Native English speakers\n3. Willing and able to consent to the protocol and undergo imaging and neuropsychological testing at the specified time points\n4. Patients with PPA will be asked to bring a study partner to all visits\n5. Patients with very mild or mild PPA, patients with amnestic mild cognitive impairment and cognitively unimpaired participants with preclinical AD will be included.\n\nExclusion Criteria:\n\n1. History of head trauma involving loss of consciousness or alteration in consciousness\n2. Another major neurologic or psychiatric condition\n3. Known presence of a structural brain lesion (e.g. tumor, cortical infarct)\n4. Any contraindication to MRI, such as presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments, or foreign objects in the eyes, skin, or body\n5. Longstanding premorbid history (i.e. longer than 10 years) of alcohol or substance abuse with continuous abuse up to and including the time that the symptoms leading to clinical presentation developed\n6. Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the study protocol.\n7. Unwilling to return for follow-up, undergo neuropsychological testing, TMS, and MR imaging\n8. History of unprovoked seizures (i.e., seizures that occur in the absence of a clear provocation such as hyponatremia, hypoglycemia, etc.).\n9. Subjects who have a first degree relative (e.g., father, mother or sibling) with a seizure disorder.\n10. Subjects currently taking, or plan to take, medications which are highly epileptogenic. These include: clozapine, high doses of bupropion (i.e., greater than 400mg daily), diphenhydramine, cyclosporine, isoniazid, imipenem, chloroquine, tramadol and theophylline.\n11. Subjects actively on anti-amyloid treatments. This is because they are at risk for bleeding due to amyloid-related imaging abnormalities (ARIA) that could provoke seizures.",true,"40 Years","99 Years",{"count":63,"type":20},30,[65],"EARLY_PHASE1","In this research study we want to learn more about the effects of non-invasive brain stimulation on memory and brain-network function in cognitively unimpaired older adults and in patients with amnestic mild cognitive impairment (aMCI).\n\nThis study will use a form of non-invasive brain stimulation called repetitive Transcranial Magnetic Stimulation (rTMS). rTMS will slightly alter activity in an area of your brain that controls memory. Changes resulting from this stimulation will be measured with behavioral tests of memory and general cognition, as well as by taking images of your brain with Magnetic Resonance Imaging (MRI).\n\nParticipants will come in for one baseline visit followed by 10 days of daily rTMS study visits (Monday through Friday) and an evaluation visit. Then, there will be a 2-week break. After this break, they will return for another baseline visit, an additional 10 days of rTMS, and a final evaluation visit.",[29,68,69,32],"Mild Cognitive Impairment","Logopenic Progressive Aphasia",[71],"Transcranial Magnetic Stimulation","2026-05-05",{"date":74,"type":43},"2026-05-06",{"date":76,"type":43},"2023-05-01",{"date":78,"type":20},"2027-03-31",{"name":80,"class":50},"Massachusetts General Hospital"]